Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML

Acute myeloid leukaemia (AML) carrying internal tandem duplication (ITD) of Fms-Like Tyrosine kinase 3 (FLT3) gene is associated with high risk of relapse and poor clinical outcome upon treatment with conventional chemotherapy. FLT3 inhibitors have been approved for the treatment of this AML subtype but leukaemia relapse remains to be a major cause of treatment failure. Mechanisms of drug resistance have been proposed, including evolution of resistant leukaemic clones; adaptive cellular mechanisms and a protective leukaemic microenvironment. These models have provided important leads that may inform design of clinical trials. Clinically, FLT3 inhibitors in combination with conventional chemotherapy as induction treatment for fit patients; with low-intensity treatment as salvage treatment or induction for unfit patients as well as maintenance treatment with FLT3 inhibitors post HSCT hold promise to improve survival in this AML subtype.

• Publication year

  2020

• Venue

  International Journal of Molecular Sciences

• Publication date

  2020-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/ijms21041537PMID 32102366PMCID 7073218
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

  2020cited by this paper
• Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms‐like tyrosine kinase 3

  2020cited by this paper
• Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

  2019cited by this paper
• Niche

  2019cited by this paper
• Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions

  2019cited by this paper
• A Phase II Single-Arm Open-Labeled Study Evaluating Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) in Newly Diagnosed or Relapsed/Refractory AML Carrying FlT3-ITD

  2019influential reference
• Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.

  2019cited by this paper
• Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3‐internal tandem duplication mutation–positive acute myeloid leukemia

  2019cited by this paper
• Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.

  2019cited by this paper
• A Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and Leukemia.

  2019cited by this paper
• Clonal selection with Ras pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia.

  2019influential reference
• Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD+ acute myeloid leukemia

  2019cited by this paper
• Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia.

  2019cited by this paper
• Radius: Midostaurin (mido) Plus Standard of Care (SOC) after Allogeneic Stem Cell Transplant (alloSCT) in Patients (pts) with FLT3-Internal Tandem Duplication (ITD)–Mutated Acute Myeloid Leukemia (AML)

  2019cited by this paper
• Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL

  2019cited by this paper
• Role of CYP3A4 in bone marrow microenvironment-mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors.

  2019cited by this paper
• Cells

  2019cited by this paper
• Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity.

  2019cited by this paper
• FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells

  2019cited by this paper
• Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.

  2018cited by this paper
• Sorafenib Combined with 5‐azacytidine in Older Patients with Untreated FLT3‐ITD Mutated Acute Myeloid Leukemia

  2018cited by this paper
• T‐cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3‐ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

  2018cited by this paper
• Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

  2018cited by this paper
• Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

  2018cited by this paper
• The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow

  2018cited by this paper
• Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia.

  2018cited by this paper
• Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial

  2018cited by this paper
• CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

  2018cited by this paper
• The combination of FLT 3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT 3 / ITD acute myeloid leukemia cells

  2017cited by this paper
• CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.

  2017cited by this paper
• Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study

  2017cited by this paper
• Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant

  2017cited by this paper
• FGF 2 from marrow microenvironment promotes resistance to FLT 3 inhibitors in acute myeloid leukemia

  2017cited by this paper
• Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

  2017cited by this paper
• Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.

  2017influential reference
• Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms‐like tyrosine kinase 3‐mutated acute myeloid leukemia

  2017cited by this paper
• The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with FLT3‐ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial: Abstract: AML‐014

  2017cited by this paper
• Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.

  2016cited by this paper
• Mesenchymal Inflammation Drives Genotoxic Stress in Hematopoietic Stem Cells and Predicts Disease Evolution in Human Pre-leukemia.

  2016cited by this paper
• Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia

  2016cited by this paper
• Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells

  2016cited by this paper
• The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells

  2016cited by this paper
• Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3‐ITD acute myeloid leukaemia in first complete remission

  2016cited by this paper
• Genomic Classification and Prognosis in Acute Myeloid Leukemia.

  2016cited by this paper
• FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.

  2016cited by this paper
• Metabolism-related pharmacokinetic drug−drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations

  2015cited by this paper
• Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

  2015cited by this paper
• Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.

  2015cited by this paper
• FLT3 D835 Mutations Confer Differential Resistance to Type II FLT3 Inhibitors

  2015cited by this paper
• Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML

  2015cited by this paper
• Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia

  2015cited by this paper
• Secondary mutations as mediators of resistance to targeted therapy in leukemia.

  2015cited by this paper
• Phase I/II trial of the combination of midostaurin (PKC412) and 5‐azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome

  2015cited by this paper
• Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 "Gatekeeper" F691L Mutation with PLX3397.

  2015cited by this paper
• Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia

  2015cited by this paper
• Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia

  2015cited by this paper
• International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia.

  2014cited by this paper
• Nice neighborhood: emerging concepts of the stem cell niche.

  2014cited by this paper
• Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.

  2013cited by this paper
• Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

  2013cited by this paper
• Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.

  2013cited by this paper
• A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML.

  2013cited by this paper
• Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

  2012cited by this paper
• SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.

  2012cited by this paper
• Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

  2012cited by this paper
• Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns

  2012cited by this paper
• FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.

  2011cited by this paper
• Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution.

  2011cited by this paper
• Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.

  2011cited by this paper
• Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia

  2011cited by this paper
• Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications

  2011cited by this paper
• Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

  2011cited by this paper
• p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12.

  2011cited by this paper
• Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

  2010cited by this paper
• U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome.

  2009cited by this paper
• Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.

  2009cited by this paper
• Structural and numerical variation of FLT3/ITD in pediatric AML.

  2008cited by this paper
• The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

  2008cited by this paper
• Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.

  2008cited by this paper
• Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype

  2007cited by this paper
• Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML.

  2007cited by this paper
• Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.

  2006cited by this paper
• Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.

  2006cited by this paper
• Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1alpha(CXCL12)/CXCR4 axis.

  2005cited by this paper
• AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.

  2005cited by this paper
• Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

  2005cited by this paper

• FLT3 Inhibitors Induce p53 Instability, Driven by STAT5/MDM2/p53 Competitive Interactions in Acute Myeloid Leukemia.

  2025cites this paper
• Functional combination of resveratrol and midostaurin induces cytotoxicity to overcome acquired midostaurin resistance in FLT3-ITD expressing acute myeloid leukemia cells

  2025cites this paper
• Heme oxygenase 1 confers gilteritinib resistance in FLT3-ITD acute myeloid leukemia in a STAT6-dependent manner

  2025cites this paper
• Identification of furo[2,3-d]pyrimidin-4-ylsulfanyl-1,3,4-thiadiazole derivatives as novel FLT3-ITD inhibitors.

  2024cites this paper
• Targeting rapid TKI‐induced AXL upregulation overcomes adaptive ERK reactivation and exerts antileukemic effects in FLT3/ITD acute myeloid leukemia

  2024cites this paper
• Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia.

  2024cites this paper
• FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives.

  2024cites this paper
• WTAP and m6A-modified circRNAs modulation during stress response in acute myeloid leukemia progenitor cells

  2024cites this paper
• Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1.

  2024cites this paper
• FLT3 and IDH1/2 Inhibitors for Acute Myeloid Leukemia: Focused Clinical Narrative Review of Forthcoming Drugs from an Indian Context

  2024cites this paper
• The Dual PIM/FLT3 Inhibitor MEN1703 Combines Synergistically With Gilteritinib in FLT3‐ITD‐Mutant Acute Myeloid Leukaemia

  2024cites this paper
• PRDM16 Induces Methylation of FLT3 to Promote FLT3-ITD Signaling and Leukemia Progression.

  2024cites this paper
• Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment

  2023cites this paper
• Downregulation of RCN1 promotes pyroptosis in acute myeloid leukemia cells

  2023cites this paper
• Discovery of 2-Aminopyrimidine Derivatives as Potent Dual FLT3/CHK1 Inhibitors with Significantly Reduced hERG Inhibitory Activities.

  2023cites this paper
• A new cyclin-dependent kinase-9 inhibitor A09-003 induces apoptosis in acute myeloid leukemia cells with reduction of myeloid cell leukemia sequence-1 protein.

  2023cites this paper
• Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia

  2023cites this paper
• Nuclear factor Nrf2 promotes glycosidase OGG1 expression by activating the AKT pathway to enhance leukemia cell resistance to cytarabine

  2022influential citation
• Identification of 2-Aminopyrimidine Derivatives as FLT3 Kinase Inhibitors with High Selectivity over c-KIT.

  2022cites this paper
• Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions.

  2022cites this paper
• A Novel BRD Family PROTAC Inhibitor dBET1 Exerts Great Anti-Cancer Effects by Targeting c-MYC in Acute Myeloid Leukemia Cells

  2022cites this paper
• Newly Developed Treatments for Acute Lymphoblastic and Acute Myeloid Leukemia

  2022cites this paper
• Modulation of FLT3-ITD and CDK9 in acute myeloid leukaemia cells by novel proteolysis targeting chimera (PROTAC).

  2022cites this paper
• PRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371.

  2022cites this paper
• Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches

  2022cites this paper
• Advances and Future Goals in Acute Myeloid Leukaemia Therapy

  2022cites this paper
• HSP70 and FLT3-ITD: Targeting chaperone system to overcome drug resistance

  2021cites this paper
• Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.

  2021cites this paper
• Novel antigens of CAR T cell therapy: New roads; old destination

  2021cites this paper
• LY294002 Is a Promising Inhibitor to Overcome Sorafenib Resistance in FLT3-ITD Mutant AML Cells by Interfering With PI3K/Akt Signaling Pathway

  2021cites this paper
• Discovery and structure - activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors.

  2021cites this paper
• Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia

  2021cites this paper
• 3H-Pyrazolo[4,3-f]quinoline-Based Kinase Inhibitors Inhibit the Proliferation of Acute Myeloid Leukemia Cells In Vivo.

  2021cites this paper
• All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status

  2021cites this paper
• Role of FLT3 in Acute Myeloid Leukemia: Molecular mechanisms and Therapeutic opportunities Moharram, Sausan

  2021cites this paper
• The war on clones: a Darwinian enigma.

  2021cites this paper
• FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review

  2021influential citation
• Combining Mass Spectrometry-Based Phosphoproteomics with a Network-Based Approach to Reveal FLT3-Dependent Mechanisms of Chemoresistance

  2021cites this paper
• Drug Resistance in Hematological Malignancies

  2020cites this paper
• DrugSniper, a Tool to Exploit Loss-Of-Function Screens, Identifies CREBBP as a Predictive Biomarker of VOLASERTIB in Small Cell Lung Carcinoma (SCLC)

  2020influential citation
• Theoretical Studies Aimed at Finding FLT3 Inhibitors and a Promising Compound and Molecular Pattern with Dual Aurora B/FLT3 Activity

  2020cites this paper
• Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia

  2020cites this paper
• Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.

  2020cites this paper
• FLT3 inhibitors in the treatment of Acute Myeloid Leukemia: current status and future perspectives.

  2020cites this paper
• Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence

  2020cites this paper
• Cutting Edge Molecular Therapy for Acute Myeloid Leukemia

  2020cites this paper